Exploiting a Novel DNA Repair Defect in Ewing Sarcoma |
Dana-Farber Cancer Institute / Shuhei Asada, MD/PhD |
Young Investigator Grants |
2024 |
Massachusetts |
Application of single-cell approaches to investigate the developmental origin and transformation steps of osteosarcoma |
Dana-Farber Cancer Institute / James Morrow, MD/PhD |
Young Investigator Grants |
2024 |
Massachusetts |
Improving homing and activity of CAR T cells in pediatric sarcomas |
University of Colorado Denver / Joselyn Cruz Cruz, PhD |
Young Investigator Grants |
2024 |
Colorado |
Defining how thymic expression of oncofetal antigens hinders the efficacy of pediatric-cancer focused immunotherapies |
Stanford University / Adrienne Long, MD/PhD |
Young Investigator Grants |
2024 |
California |
Understanding the role of CDK8 in protein synthesis for treating MYC-driven medulloblastoma |
University of Colorado Denver / Dong Wang, PhD |
Young Investigator Grants |
2024 |
Colorado |
Targeting Oncogenic N-MYC Complexes in High-Risk Neuroblastoma |
The Regents of the University of California San Francisco / Bo Qiu, MD/PhD |
Young Investigator Grants |
2023 |
California |
Empowering specificity of AML immunotherapies by HSC engineering |
Aflac Cancer Center and Blood Disorders Service of Children’s Healthcare of Atlanta / Pietro Genovese |
Catalyst Grants |
2023 |
Georgia |
Immunoglobulin High-Throughput Sequencing for Refining Risk Stratification in Infant B-ALL |
University of Rochester / Carol Fries Simpson, MD |
Reach Grants |
2023 |
New York |
Mutagenesis and disease progression in RUNX1 mutant blood stem cells is caused by inflammation-induced hyperactive signaling and supraphysiological mitochondrial ROS |
St. Jude Children’s Research Hospital / Dirk Loeffler, PhD |
RUNX1 Early Career Investigator Grants |
2023 |
Tennessee |
Identification of Aberrantly Methylated Differentially Expressed Genes to Distinguish High- vs. Low-Risk Retinoblastoma |
Children’s Hospital Los Angeles / Jesse Berry, MD |
Reach Grants |
2023 |
California |